上海市锦天城律师事务所 关于深圳市卫光生物制品股份有限公司 2025 年度向特定对象发行股票的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 | | | | 二十二、结论意见 46 | | --- | 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于深圳市卫光生物制品股份有限公司 2025 年度向特定对象发行股票的 法律意见书 一、本所及本所经办律师依据《证券法》《律师事务所从事证券法律业务管 理办法》（以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业 务执业规则（试行）》《公开发行证券公司信息披露的编报规则第 12 号—公开 发行证券的法律意见书和律师工作报告》（以下简称"《编报规则 12 号》"）等 法律、法规、规章和规范性文件的规定及本法律意见书出具日以前已经发生或者 存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充 分的核查验证，保证本法律意见书所认定的事实真实、准确、完整，所发表的结 论性意见合法、准确，不存在虚假记载、误导性 ...

深圳市卫光生物制品股份有限公司 审计报告 大信审字[2025]第 5-00037 号 大信会计师事务所(特殊普通合伙) WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行企 报告编码:京25S7 6-1-1 审计报告 大信审字[2025]第 5-00037 号 深圳市卫光生物制品股份有限公司全体股东: 一、审计意见 我们审计了深圳市卫光生物制品股份有限公司(以下简称"贵公司")的财务报表,包 括 2024年12月 31 日的合并及母公司资产负债表,2024年度的合并及母公司利润表、合并及 母公司现金流量表、合并及母公司股东权益变动表,以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 贵公司 2024年 12月 31日的合并及母公司财务状况以及 2024年度的合并及母公司经营成果 和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐 ...

卫光生物（002880.SZ）9月30日在投资者互动平台表示，截至目前，卫光生命科学园一期产业空间去化 率100%，二期产业空间去化率约71％。 （记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：请问贵司的卫光生命科技园现在的入驻率是多少？ ...

Core Viewpoint - The company has successfully acquired the land use rights for a specific plot in Shenzhen, indicating a strategic move to expand its operations and assets in the region [1] Group 1 - On August 15, 2025, the company held its fourth board meeting and approved a proposal to participate in the auction for state-owned land use rights [1] - The company announced on September 8, 2025, that it successfully obtained the land use rights for plot A628-0045 in the Guangming District of Shenzhen [1] - A formal contract for the land use rights was signed with the Shenzhen Municipal Planning and Natural Resources Bureau Guangming Management Bureau [1]

Core Viewpoint - Weigao Biological (002880.SZ) successfully acquired the land use rights for a specific plot in Shenzhen, marking a significant step in its expansion strategy [1] Group 1 - The company announced the successful bidding for the land use rights of plot A628-0045 located in the Guangming District of Shenzhen [1] - The acquisition was part of a public auction organized by Shenzhen Trading Group Co., Ltd. [1] - The company has signed the land use rights transfer contract with the Shenzhen Planning and Natural Resources Bureau Guangming Management Bureau [1]

证券代码:002880 证券简称:卫光生物 公告编号:2025-044 深圳市卫光生物制品股份有限公司 关于签署国有建设用地使用权出让合同的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）于2025年8月15日召开 第四届董事会第二次会议，审议通过了《关于拟参与竞拍国有建设用地使用权的 议案》，同意公司参与竞拍深圳市国有建设用地使用权出让公告（深土交告〔2025〕 28号）公示的A628-0045宗地使用权。 2025年9月8日，公司披露了《关于竞得土地使用权并签署成交确认书的公告》 （公告编号：2025-043），公司参加深圳交易集团有限公司土地矿业权业务分公 司举办的光明区马田街道宗地号为A628-0045的国有建设用地使用权挂牌出让活 动，成功竞得上述地块的使用权，并签署了《成交确认书》（深土交成〔2025〕 29号）。 近日，公司与出让人深圳市规划和自然资源局光明管理局签署了《深圳市国 有建设用地使用权出让合同》[合同编号：深地合字（2025）7018号]。现将有关 情况公告如下： 一、合同的主要内容 ...

Core Viewpoint - The company successfully acquired the land use rights for a plot in Shenzhen for RMB 60.4 million, which aligns with its strategic plan to develop an intelligent industrial base [1][2]. Group 1: Land Acquisition Details - The company participated in the bidding for the land use rights of plot A628-0045, which was publicly announced by the Shenzhen Municipal Government [1]. - The land area is 69,986.43 square meters, with a usage period of 30 years [1]. - The land is categorized under the encouraged industry category for "new drug development and industrialization" as per the "Industrial Structure Adjustment Guidance Catalog (2024)" [1]. Group 2: Purpose and Impact of the Acquisition - The purpose of acquiring the land is to meet the needs of the company's intelligent industrial base project, which is in line with its development strategy and aims for high-quality growth [2]. - The funding for the land acquisition comes from the company's own or self-raised funds, ensuring no adverse impact on its main business or financial stability [2]. - Once the new industrial base is operational, the company plans to relocate its operations and will cooperate with local government authorities to vacate the current facility [2].

Major Events - Robotech plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Leo Group plans to issue H-shares and list on the Hong Kong Stock Exchange [1] Performance - Tianji shares gain high market attention for solid-state battery concept; subsidiary has obtained patents for lithium sulfide materials and their preparation methods [1][1] - Weiguang Bio has successfully acquired land use rights and signed a transaction confirmation [1] - Gansu Energy's Changle Company has officially put the 5th unit of the 2×1000 MW coal-fired unit expansion project into commercial operation [1] - Zhaoxin shares' largest shareholder did not trade company stocks during abnormal trading fluctuations [1] - Electric Alloy's shareholder plans to acquire indirect shares through block trading, involving no more than 2.4 million shares [1] - Nanchin Technology plans to issue convertible bonds to raise no more than 1.933 billion yuan for research and industrialization of power management chips in the intelligent computing field [1] - Ningbo Ocean plans to invest in the establishment of two overseas companies [1] - Jidian shares received 913 million yuan in national renewable energy subsidy funds in August [1] - Shennong Group sold 166,400 pigs in August, generating sales revenue of 285 million yuan [1] - Tianbang Food sold 529,700 commercial pigs in August, with sales revenue of 621 million yuan [1]

Core Viewpoint - The company, Weiguang Biological (002880.SZ), successfully acquired a piece of industrial land in Guangming District for 60.4 million yuan, indicating its strategic expansion in the region [1] Group 1: Company Actions - Weiguang Biological participated in a land auction held by Shenzhen Trading Group Co., Ltd. on September 5, 2025 [1] - The company won the bidding for the state-owned construction land use rights for a total price of 60.4 million yuan [1] - The acquired land has a total area of 69,986.43 square meters and is designated for general industrial use [1]

Group 1 - The company, Weiguang Biological (002880.SZ), successfully acquired the land use rights for a state-owned construction land in Guangming District, Shenzhen, for a price of 60.4 million yuan [1] - The land area is approximately 69,986.43 square meters, designated for general industrial use [1] - The acquisition was part of a public bidding event organized by Shenzhen Trading Group Co., Ltd. on September 5, 2025 [1]